Files Preview
Files Preview
Market Strategy
3Q24 Highlights: Solid Banks, Auto, Coal, Poultry Stocks Covered 76
Rating (Buy/Neutral/Sell): 53 / 20 / 3
Last 12m Earnings Revision Trend: Neutral
• 3Q24 net profit: Banks, auto, coal, and poultry posted strong Sectors Top Picks
performances; challenges persist in tobacco, healthcare, OVERWEIGHT
telecommunication, and cement. Overall, 3Q24 bottomline saw a 9.6% QoQ Banks BBRI, BBNI, BMRI,
rise (+11.6% YoY), with total 9M24 earnings up 4.1% YoY or 76% of forecasts, BBTN
ie aligning with expectations. These numbers are based on 9M24 earnings of Cement INTP
56 out of the 76 firms we cover. Post results, we adjusted earnings, raising Healthcare KLBF
projections for Astra International (ASII), United Tractors (UNTR), Aneka Oil & gas MEDC, ELSA
Tambang (ANTM IJ, BUY, TP: IDR1,800), Japfa Comfeed (JPFA IJ, BUY, TP: Property – industrial estates DMAS
IDR2,650), and PP London Sumatra Indonesia (LSIP IJ, BUY, TP: IDR1,400), Property – residential developer PWON, BSDE
thanks to strong performances and still-robust 4Q24 outlooks, while Telecommunication EXCL
lowering our forecast for Kencana Energi Lestari (KEEN IJ, BUY, TP: IDR850).
• Banks met expectations on strong loan growth and robust non-II. Banks like NEUTRAL
Bank Central Asia (BBCA IJ, BUY, TP: IDR12,060), Bank Mandiri (BMRI IJ,
Auto & autoparts ASII, AUTO
BUY, TP: IDR8100), and Bank Negara Indonesia (BBNI IJ, BUY, TP: IDR6,710)
Coal UNTR
saw improved asset quality and healthy loan yields. BBCA raised its FY24
loan growth target while Bank Rakyat Indonesia (BBRI) showed NIM and Consumer AMRT, ICBP
non-II growth. Bank BJB (BJBR IJ, NEUTRAL, TP: IDR920) faced challenges – Metal mining MDKA, INCO
affected by lower NIM; no thanks to higher Bank Indonesia (BI) rates. Plantation LSIP
• Auto & autoparts outperformed on strong demand for used vehicles and Poultry JPFA
replacement markets despite weak new vehicle sales. ASII’s earnings were Pulp & paper INKP
boosted by its mining, gold, and financial services segments while Astra Tobacco HMSP
Otoparts (AUTO) benefited from robust trading and manufacturing
recoveries. Both achieved c.85% of their FY24F earnings. Analyst
• Consumer had mixed results: Indofood CBP (ICBP) and Indofood Sukses
(INDF IJ, BUY, TP: IDR8,000) doing well on FX gains and solid demand. Firms Andrey Wijaya
like Mayora Indah (MYOR IJ, BUY, TP: IDR3,300) and Unilever Indonesia +6221 5093 9846
(UNVR IJ, NEUTRAL, TP: IDR2,170) saw challenges from rising material costs [email protected]
and increased competition. Healthcare and telecommunications
underperformed on lower patient volume and rising costs (healthcare) and
reduced data demand and subscriber growth (telecoms).
• Coal and oil & gas, robust commodity prices supported strong performance. Recently published strategy reports
UNTR and Adaro Energy (ADRO IJ, BUY, TP: IDR3,900) led coal while
● Unity, Self-Sufficiency, And Sustainable Growth
Perusahaan Gas Negara (PGAS IJ, NEUTRAL, TP: IDR1,440) and Medco
Energi Internasional (MEDC) showed resilience in oil & gas on higher ● Hopeful Despite Recent Volatility, 4Q24 Sector Picks
distribution spreads and improved associate income. Metal mining was ● IKN Progress, Fiscal Strategies, Retail Sector Insights
mixed: Vale Indonesia (INCO IJ, TRADING BUY, TP: IDR4,300) was ● Positive Market Outlook Driven By 2025 Budget
pressured by high energy costs while ANTM was propped by strong demand. ● Strong 1H24; Healthcare, Poultry, Auto Outperform
• Infrastructure, toll road, cement, and property development: Mixed results. ● Tactical Strategies During The Transition Period
Infrastructure showed YoY growth from tariff increases, though QoQ ● Post 1Q24 Earnings Tactical Strategy
earnings normalised due to seasonal factors. Cement faced challenges from
industry oversupply while property development saw revenue normalisation
after a strong first half, driven by recurring income from hospitality.
Target % Ups ide P/E (x) P/B (x) ROAE (%) Yield (%)
Company Name Rating
(IDR) (Downs ide) Dec-25F Dec-25F Dec-25F Dec-25F
Astra International Buy 6,300 22.9 5.8 1.1 18.1 5.0
Astra Otoparts Buy 2,800 13.4 7.1 0.8 11.6 4.4
Bank Rakyat Indonesia Buy 5,900 25.0 10.0 2.0 19.9 6.9
Elnusa Buy 650 38.3 4.1 0.6 15.9 9.1
Indofood CBP Buy 13,800 12.0 13.7 2.7 21.6 3.4
Kalbe Farma Buy 1,970 23.9 21.0 3.0 14.5 2.5
Medco Energi Internasional Buy 1,900 49.0 5.1 0.8 18.2 5.5
Merdeka Copper Gold Buy 3,100 33.6 37.1 3.3 9.2 -
S umber Alfaria Trijaya Buy 3,800 15.5 39.7 6.9 25.0 -
United Tractors Buy 35,000 28.0 5.3 1.1 20.9 7.6
Source: Company data, RHB P/E (x) P/B (x) ROAE Yield (%)
Dec-25F
5.8 Dec-25F
1.1 (%)0.2 Dec-25F
0.0
See important disclosures at the end of this report
1
7.1 0.8 0.1 0.0
Market Strategy Indonesia Strategy
8 November 2024 Market Outlook | Market Strategy
BBCA In line Robust 3Q24 results in line, however 4Q opex tends to be seasonally higher, which could dampen bottomline. On the back of robust
loans growth, management raised its FY24 loans growth guidance to 10-12% from 8-10%.
BMRI In line Solid 3Q24 net profit met expectations, aided by increased non-II and reduced provisions. Consolidated NIM grew QoQ, though
bank-only NIM declined due to rising funding costs. Loan demand stayed strong, with stable asset quality and improved LAR and NPL
ratios.
BBNI In line 3Q24 results aligned with expectations, highlighted by NIM growth from increased loan yields and lower deposit costs. BBNI
management remains optimistic, focusing on strong loan demand, improving liquidity, and expanding low-cost deposits.
BBRI In line 3Q24 earnings increased 11.2% QoQ, supported by higher non-II and slight NIM gains, with 9M24 earnings up 2.4% YoY. Improved
asset quality and recovery rate, alongside lower expected credit costs, bolster 4Q24’s growth prospects.
BJBR In line 3Q24 net profit rose 21.1% QoQ, meeting expectations, though 9M24 earnings dropped 19% YoY due to NIM pressures from higher
BI rates. Loan growth lagged, but CASA improved, with higher 4Q24 credit costs expected.
BNGA In line Stable 3Q24 net profit, in line with expectations. Loan growth reached 6.4% YoY, excluding mortgages, with focus on profitability.
Lower NIM of 4.07% led to revised FY24F guidance, while improved asset quality and reduced LAR prompted CoC guidance below
1%, prioritising selective, high-yield, low-risk loans.
Overall In line In 3Q24, major Indonesian banks mostly aligned with expectations, driven by loan growth and robust non-interest income. BBCA
raised its FY24 loan growth target to 10-12% despite anticipated 4Q opex pressure. BMRI saw NIM improvement at the
consolidated level, though funding costs affected the bank-only segment NIM. BBNI's results benefited from loan yield increases
and focus on low-cost deposits, while BBRI's earnings rose with improved asset quality and a strong recovery rate. BJBR achieved
QoQ net profit growth but faced YoY declines from BI rate impacts. BNGA focused on high-yield loans, revising its CoC guidance
below 1% due to better asset quality and lower LAR.
Source: Company data, RHB
Auto & autoparts: Surpass 3Q24 with strong performance in finance and used vehicles
ASII's 3Q24 earnings exceeded expectations, driven by its mining contracting, gold, and
financial services sectors. Despite the normalisation of coal prices, ASII achieved strong
results, largely supported by sales volumes from its mining activities and a robust
performance in financial services. This resilience highlights the company’s ability to maintain
profitability even with changes in commodity prices.
AUTO also performed well, with its 3Q24 trading revenue remaining strong while
manufacturing revenue showed signs of recovery. The total revenue in 3Q24 was strong, and
net profit continued to be bolstered by equity income, particularly from the replacement
market. This indicates robust demand in the used vehicle and replacement sectors, which
offset weaker sales in new vehicles YoY.
Overall, ASII and AUTO’s performances reflect their strategic adaptability, focusing on high-
demand areas such as financial services, used vehicles, and mining amidst changing market
conditions. Both companies achieved c.85% of their full-year forecasts, with ASII at 86% and
AUTO at 83%, positioning them well to meet or exceed their year-end targets.
ASII's strong 9M24 earnings, and management’s optimistic outlook for end-2024 and FY25
have prompted an upgrade to its FY24-25 forecasts. The company’s valuation is primarily
supported by its finance and mining segments.
Consumer: Mixed results as FX gains boost ICBP and INDF, while MYOR and
UNVR face cost pressures and market challenges
Overall, the consumer sector saw a mixed performance, with companies benefiting from
favourable exchange rates, while others faced challenges from raw material costs and market
pressures.
In 3Q24, ICBP and INDF achieved strong performances, largely driven by substantial FX gains
from the IDR’s appreciation and solid sales. INDF also benefitted from improved margins.
Cisarua Mountain Dairy (CMRY IJ, BUY, TP: IDR5,700) recorded a solid sales performance,
remaining in line with expectations. However, MYOR struggled due to increased raw material
costs for cocoa and coffee, which compressed margins, leading to a below-expectations
performance. Similarly, UNVR faced weak earnings due to sluggish sales and rising operating
expenses, compounded by intensifying competition and boycott issues.
ICBP's 9M24 growth was primarily driven by sales volumes, with sales of noodles up 7% YoY
and dairy up 8%, with modest gains in snacks, seasonings, nutrition, and beverages. Noodle
sales volumes rose 5% domestically and 23% in overseas markets in 3Q24, with strong
demand in Egypt, Turkey, and key markets. New launches, like the Korean Ramyeon series,
gained traction, with marketing focused on social media to target younger consumers. Ice
cream products also performed well, albeit with a small revenue share, and the company
maintained its A&P-to-revenue ratio guidance at 4%.
INDF's growth was supported by strong performances in Bogasari, LSIP, and ICBP. Bogasari’s
volumes rose 12%, maintaining a 6-8% EBIT margin, while ICBP expects 5-8% revenue growth
from sales volumes. LSIP exceeded expectations, benefiting from high CPO prices and
favourable tax changes. We revised up LSIP’s FY24F-26F earnings by 24%, 24%, and 21%
after reducing our unit cost assumptions, raising interest income, and lowering effective tax
rates.
CMRY achieved a 45.5% GPM in 3Q24, and expects this to stabilise at 42-44% due to
potential raw material price fluctuations. Growth in the dairy segment is driven by UHT milk
sales volumes and a recovery in yogurt product sales, with new products gaining traction.
CMRY is expanding its distribution, especially in general trade, and investing heavily in
marketing. It anticipates a 20-22% ratio of marketing expenses to revenue to boost yogurt
consumption.
Retail: Mixed results; some companies saw strong sales, others faced margin
pressures and seasonal challenges
Retail companies saw a mixed performance in 3Q24, with some benefiting from solid sales
growth, while others faced challenges. MAP Aktif Adiperkasa (MAPA IJ, BUY, TP: IDR930)
outperformed expectations with strong sales growth and effective cost controls despite 3Q
being a low season. Erajaya Swasembada (ERAA IJ, NEUTRAL, TP: IDR420) saw robust
profitability driven by higher sales volumes, particularly in the affordable product segment,
and expanded verticals.
Mitra Adiperkasa’s (MAPI IJ, BUY, TP: IDR1,800) performance was impacted by the soft
recovery in its F&B business and the end-of-season sales, which pressured margins. Aspirasi
Hidup Indonesia’s (ACES IJ, TRADING BUY, TP: IDR815) results were in line with historical
trends, with its 9M24 earnings achieving 62-67% of full-year targets, consistent with past
years. Meanwhile, Sumber Alfaria Trijaya’s (AMRT IJ, BUY, TP: IDR3,800) 9M24 earnings met
expectations, achieving c.60% of our and consensus’ full-year projections.
Overall, the sector displayed a mixed outcome, with some companies thriving due to volume
growth and strategic cost management, while others struggled with seasonal and segment-
specific pressures.
Tobacco: Challenges in 9M24 amid rising excise taxes, downtrading trends, and
limited price adjustments
The tobacco sector faced a challenging 9M24, with HMSP, GGRM, and WIIM all reporting
weaker earnings that were below expectations. HMSP's earnings were impacted by higher
operational expenses, including salaries and promotions, along with rising excise taxes and
raw material costs. A shrinking market share due to consumer downtrading also limited sales
growth.
GGRM’s earnings suffered from an insufficient ASP increase, which was unable to offset rising
excise taxes. While the company focused on volume growth in the machine-rolled kretek
(SKM) segment, downtrading led to modest sales growth, while sales in the hand-rolled kretek
(SKT) segment declined. Elevated operating expenses further reduced net margins.
WIIM experienced stagnant volume growth, capped by tier-2 market limits, and has not raised
prices since January, eroding its GPM to 6% due to rising excise taxes. The company expects
performance improvements in 4Q24 if sales increase as anticipated.
Overall, the sector’s weak 9M24 performance is attributed to downtrading trends, high excise
taxes, and less aggressive ASP hikes, which hindered market share recovery compared to tier-
2 competitors.
Healthcare: Mixed 9M24 numbers amid patient volume decline and purchasing
power challenges; KLBF’s pharmaceutical division is a bright spot
The healthcare sector recorded mixed 9M24 numbers, with overall earnings falling below
expectations due to challenges related to patient volume and purchasing power. Both Mitra
Keluarga Karyasehat (MIKA IJ, BUY, TP: IDR3,500) and Hermina Medikaloka (HEAL IJ, BUY,
TP: IDR1,700) faced a decline in patient volume, which dampened their performance. The
lower numbers were also attributed to the high base, limitations from private insurance
patients, and Social Security (BPJS) restrictions – these factors jointly pressured hospital
revenues.
Kalbe Farma (KLBF IJ, BUY, TP: IDR1,970) did relatively well, with its pharmaceutical division
meeting expectations and contributing positively to its overall performance. However, Sido
Muncul (SIDO IJ, NEUTRAL, TP: IDR620) struggled with weak sales, especially in its herbal
and supplement segment, as lower consumer purchasing power dampened the demand for
discretionary health products.
Overall, the healthcare sector’s 9M24 results were impacted by external pressures, including
soft demand and insurance-related constraints, with KLBF being the exception due to the
steady performance of its pharmaceutical segment.
HEAL 147 152 125 -17.9% -14.7% 349 468 34.2% 728 64% 602 78% Below
KLBF 536 843 573 -32.0% 7.0% 2,065 2,378 15.2% 3,207 74% 3,261 73% In line
SIDO 138 218 170 -22.2% 22.5% 587 778 32.7% 1,310 59% 1,197 65% Below
Total 1,054 1,525 1,140 -25.2% 8.1% 3,687 4,497 22.0% 6,468 70% 6,231 72% Below
Telecommunications: Weak 3Q24 as ISAT and TLKM struggle with declining data
demand, ARPU and subscriber bases
The sector faced a challenging 3Q24, with both ISAT and Telkom Indonesia (TLKM IJ, BUY,
TP: IDR4,780) reporting earnings below expectations. ISAT booked a 20.6% QoQ decline in
net profit, impacted by slower data consumption and a decrease in subscriber numbers. Its
EBITDA eroded due to weaker topline growth, which highlighted a difficult quarter for the
telecom industry.
TLKM’s results also deteriorated, with revenue down 9.4% YoY and a slight decline in EBITDA
growth. The company faced challenges from declining ARPU and lower data yields in mobile
revenue, while other segments, such as interconnection and enterprise, also saw declines.
TLKM managed to achieve low single-digit EBITDA growth and some margin expansion QoQ,
although it remained lower on a YoY basis.
Overall, 3Q24 was a weak period for the telecommunications sector, with both ISAT and
TLKM affected by reduced data demand, lower ARPU, and subscriber base contraction.
Despite minor margin gains for TLKM, the industry struggled with overall revenue and
EBITDA declines compared to the previous year.
Overall In line BUKA and GOTO saw improvements in 9M24: Net losses narrowed for the first time, with positive core earnings and
lower adjusted LBITDA despite a decline in contribution margins, while GOTO approached the adjusted EBITDA-
breakeven point, achieved strong YoY growth in GTV, net revenue, and contribution margin, and reduced net loss by 53%.
Source: Company data, RHB
ADRO Above Operational stability, evidenced by margin efficiency (reflected in the reduction of cash costs), supported by operational
volumes that meet the targets along with a relatively defensive ASP of coal throughout the year, led to results that exceed
our and consensus expectations.
PTBA In line Cash costs surged throughout the year which was driven by heightened pre-stripping activity early in the year. As
anticipated, 9M24 GPMs stood at 18% vs 9M23’s 21%. Additionally, PTBA’s NPMs were significantly impacted (9M24:
11% vs the 5-year average of 19%) – primarily due to the anticipated normalisation of ASPs.
Overall Above The strong 9M24 performance was led by UNTR’s solid earnings, with stable mining contracting, targeted heavy
equipment sales bolstered by high-margin units, and rising gold prices, while PTBA faced higher cash costs and lower
gross and net profit margins due to increased pre-stripping activity and expected ASP normalisation - however, its
volume production is improved (in line with its seasonality).
Source: Company data, RHB
Metal mining: Mixed performances – INCO struggles with high energy costs,
while ANTM thrives on strong demand and diversification
Overall, the metal mining sector’s performance was mixed. While INCO faced significant
margin pressure due to energy costs, ANTM showed resilience, supported by its diversified
operations and strong demand. The sector outlook remains cautious, with pressures on
margins from expected ASP decreases and slower-than-expected demand recovery in
regional markets being anticipated.
INCO’s underperformance is attributed to challenges in managing margins, driven by high
energy costs, particularly for high-sulphur fuel oil required for its operations. With 9M24
earnings coming up to only 58% and 56% of our/consensus FY24F, INCO’s results are
considered as below expectations due to these high energy consumption needs impacting
overall production costs.
On the other hand, ANTM’s performance exceeded expectations, with 9M24 earnings at 92%
of the consensus FY24 estimate. The company's results were bolstered by strong gold sales
volume, a stable ASP in the nickel ore segment, and rising domestic demand, despite slight
margin pressure due to raw material costs in its gold refinery operations. ANTM’s diversified
product base, including gold and nickel, helped cushion its performance amidst challenging
conditions. We raised ANTM’s FY24-25F earnings by 6% each on the notion of higher gold
sales targets.
Oil & gas: Mixed earnings – PGAS and MEDC resilience, while AKRA faces market and
operational challenges
Overall, oil & gas’ earnings were mixed, with PGAS and MEDC showing resilience through
higher distribution spreads and improved associate income, while Elnusa (ELSA)
demonstrated stable growth. However, AKR Corporindo (AKRA) struggled with weaker sales
and profitability, impacted by market and operational challenges.
PGAS exceeded our expectations with 9M24 earnings at 84% of our FY24F forecast, driven
by an improved GPM due to a higher distribution spread and increased income from
associates. The company reported strong growth, with YoY 9M24 earnings rising by 32.7%
YoY, supported by cost controls and favourable associate income contributions.
MEDC’s earnings aligned with expectations, achieving 70% of our FY24 forecast, largely due
to a 12% YoY increase in oil and gas sales and higher associate income. A notable boost came
from Amman Mineral Internasional's (AMMN IJ, NR) substantial 808% YoY net profit
increase. However, MEDC’s results were partially offset by losses in the TransAsia Pipeline.
ELSA’s 9M24 earnings met our expectations, but were above consensus at 71% and 90% of
FY24F, attributed to steady upstream segment growth, though its downstream segment was
relatively flat. ELSA also improved its EBIT margin from 6% in 9M23 to 7% in 9M24, reflecting
operational efficiency.
By contrast, AKRA’s results fell below expectations, with 9M24 earnings at only 51% and 52%
of our and consensus FY24F. The company faced challenges due to decreased petroleum
volume, lower trading gross profit, and a 5% YoY decline in 9M24 petroleum sales amid
weaker purchasing power in the trading market. Reduced mining activity due to permit delays
also impacted AKRA’s results.
Cement & building materials: Mixed results; SMGR struggles amid oversupply,
INTP benefits from seasonality, ARNA shows steady growth
The cement & building materials sector had a mixed performance. While Semen Indonesia
(SMGR IJ, TRADING BUY, TP: IDR5,300) struggled with industry-wide oversupply and pricing
pressures, Indocement (INTP IJ, BUY, TP: IDR8,500) showed strength from seasonality but
faced normalisation risks, and Arwana Citramulia (ARNA IJ, BUY, TP: IDR870) maintains
steady growth with stable ASPs. The sector's outlook remains cautious, with expected
pressures on ASPs and potential demand fluctuations due to seasonal factors.
SMGR underperformed, achieving only 32% and 37% of our and consensus FY24 estimates
due to an industry-wide oversupply of cement capacity, which led to lower blended ASPs
despite a mid-year price hike. 9M24 earnings fell 58% YoY, reflecting ongoing pressures from
an unfavourable sales mix and competition. SMGR's earnings outlook remains cautious due to
potential further ASP challenges.
INTP delivered stronger 3Q24 results, with earnings increasing by 215.7% QoQ – meeting
expectations, as seasonality factors boosted sales. However, concerns remain over lower
blended ASPs, and 4Q24 earnings may normalise due to the year-end rainy season impact on
sales volume. 9M24 earnings reached 66% and 68% of our and consensus FY24 estimates,
demonstrating relative stability in a challenging market.
ARNA’s 9M24 performance was in line with expectations, achieving 70% of RHB's FY24
forecasts, supported by a recovery in sales volume and stable blended ASPs. The company
recorded a 14.6% QoQ increase in earnings for 3Q24, with steady demand across its product
mix. ARNA’s resilience in a competitive landscape has been attributed to its effective sales
recovery strategy and a favourable sales mix.
Figure 27: Cement & building materials’ 3Q24 results highlights (IDRbn)
(IDRbn) 3Q23 2Q24 3Q24 QoQ YoY 9M23 9M24 YoY FY24F %-RHB FY24F %- Note
RHB Cons Cons
SMGR 846 30 218 634.5% -74.2% 1,714 720 -58.0% 2,233 32% 1,970 37% Below
INTP 568 197 621 215.7% 9.3% 1,267 1,056 -16.7% 1,597 66% 1,546 68% Inline
ARNA 109 98 113 14.6% 3.3% 353 316 -10.4% 451 70% 429 74% Inline
Total 1,523 325 952 193.1% -37.5% 3,334 2,091 -37.3% 4,281 49% 3,945 53% Below
Source: Company data, RHB
Property development: PWON gains from strong recurring income while CTRA
and BSDE face project delivery normalisation
Property development was a mixed bag, with overall in-line results. Pakuwon Jati (PWON IJ,
BUY, TP: IDR550) benefitted from strong recurring income, especially in the hospitality
segment, while Ciputra Development (CTRA IJ, BUY, TP: IDR1,330) and Bumi Serpong Damai
(BSDE IJ, BUY, TP: IDR1,430) faced normalisation in project delivery and handover schedules.
Outlook for the sector remains stable, but seasonal and project-specific factors may influence
future earnings.
PWON’s 3Q24 earnings grew 58.1% QoQ and 11.8% YoY, while 9M24 earnings reached 77%
and 79% of our and consensus FY24 estimates. The company benefited from a robust rise in
recurring income, primarily driven by strong performance in its hotel segment, aligning with
expectations and contributing to a record quarterly recurring income.
CTRA, however underperformed, with its 9M24 earnings reaching only 65% and 63% of our
and consensus FY24 forecasts, attributed to weaker revenue recognition in the residential
and shop-house segment. This was partly due to normalisation following a period of higher
project completion and handovers in 1H24, affecting the QoQ performance in 3Q24, which
saw a 54.6% decline.
BSDE’s 3Q24 earnings were mainly supported by residential sales, with commercial sales
normalising due to a slower handover period. While 9M24 earnings met expectations at 87%
and 77% of our and consensus FY24 estimates, profitability was impacted by a shift in sales
mix with a lower contribution from higher-margin commercial products.
Plantation: LSIP thrives on favourable pricing and tax benefits, while AALI
struggles with high costs and weak production
Plantation’s 9M24 earnings reached 78% of our FY24 forecast, which was slightly above
expectations due to LSIP’s strong performance, despite Astra Agro Lestari (AALI IJ,
NEUTRAL, TP: IDR6,270) underperforming. LSIP outperformance was from favourable
pricing and tax benefits, while AALI faced challenges with weaker production and high costs.
The sector outlook is cautiously optimistic, as LSIP's strong fundamentals are likely to sustain
under current market conditions, while AALI may see improvement if production gains
materialise in 4Q24.
AALI reported lower-than-expected earnings, achieving only 76% and 70% of our and
consensus FY24F due to weaker FFB output and high unit costs. The company’s 3Q24
earnings declined by 16.3% QoQ and 50% YoY, reflecting ongoing operational challenges.
However, production may improve in 4Q24, although elevated unit costs could continue to
weigh on profitability.
In contrast, LSIP exceeded expectations with its 9M24 earnings reaching 90% of our FY24
estimate. The company’s strong performance was driven by robust CPO and PK prices, as well
as favourable tax rates and higher-than-expected interest income. 3Q24 YoY earnings grew
by 92.7%, demonstrating its ability to capitalise on favourable market conditions, particularly
with the higher CPO price environment and weaker USD.
LSIP’s strong earnings were further supported by a reduction in export tax structure, which,
combined with favourable market conditions, provided a significant boost to profitability. The
company’s positive outlook is expected to continue, benefiting from sustained CPO prices,
favourable tax environment, and reduced export taxes, which should help mitigate the impact
of any cost pressures. We revised up LSIP’s FY24F-26F earnings by 24%, 24%, and 21%, after
reducing our unit cost assumptions, raising interest income, and lowering effective tax rates.
Pulp & Paper: Challenging times; INKP struggles with low pulp prices, FX losses,
and rising costs despite sales volume growth
Pulp & Paper is facing a challenging environment with pressures from lower pulp prices,
unfavourable FX movements, and rising operational costs. While Indah Kiat Pulp & Paper
INKP IJ, BUY, TP: IDR13,625) saw some growth in sales volume, the sector’s profitability
remains under strain, and future performance will likely depend on recovery in pulp prices and
stabilization of FX rates.
INKP's 9M24 core earnings reached 73% of our forecast, but only 60% of consensus FY24
estimates. The weaker-than-expected performance was attributed to a combination of
factors, including lower pulp prices, forex losses, and higher operational expenses. Despite
these challenges, the company did see some improvement in pulp sales volume, though it was
not enough to offset the negative impact in other areas.
23
Indonesia *For the avoidance of doubt, the confirmation is only limited to the staff of research
department
This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This
4. RHBIB did not receive compensation for investment banking or corporate finance
research does not constitute an offering document and it should not be construed as an
services from the subject company in the past 12 months.
offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in
5. RHBIB did not receive compensation or benefit (including gift and special cost
Indonesia or to any Indonesian citizen or corporation (wherever located) or to any
arrangement e.g. company/issuer-sponsored and paid trip) in relation to the
Indonesian resident in a manner which constitutes a public offering under Indonesian
production of this report.
laws and regulations must comply with the prevailing Indonesian laws and regulations.
Singapore Thailand
Save as disclosed in the following link RHB Research Conflict Disclosures - Nov 2024
This report is issued and distributed in Singapore by RHB Bank Berhad (through its and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
Singapore branch) which is an exempt capital markets services entity and an exempt 1. RHB Securities (Thailand) PCL does not have a financial interest in the securities or
financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad other capital market products of the subject company(ies) covered in this report.
(through its Singapore branch) may distribute reports produced by its respective foreign 2. RHB Securities (Thailand) PCL is not a market maker in the securities or capital
entities, affiliates or other foreign research houses pursuant to an arrangement under market products of the subject company(ies) covered in this report.
Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in 3. None of RHB Securities (Thailand) PCL’s staff or associated person serve as a
Singapore to a person who is not an Accredited Investor, Expert Investor or an director or board member* of the subject company(ies) covered in this report
Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal 1. *For the avoidance of doubt, the confirmation is only limited to the staff of research
responsibility for the contents of the report to such persons only to the extent required department
by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore 4. RHB Securities (Thailand) PCL did not receive compensation for investment
branch) in respect of any matter arising from or in connection with the report. banking or corporate finance services from the subject company in the past 12
United States months.
5. RHB Securities (Thailand) PCL did not receive compensation or benefit (including
This report was prepared by RHB is meant for distribution solely and directly to “major” gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in
U.S. institutional investors as defined under, and pursuant to, the requirements of Rule relation to the production of this report.
15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the “Exchange
Act”) via a registered U.S. broker-dealer as appointed by RHB from time to time. Indonesia
Accordingly, any access to this report via Bursa Marketplace or any other Electronic Save as disclosed in the following link RHB Research Conflict Disclosures - Nov 2024
Services Provider is not intended for any party other than “major” US institutional and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:
investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB 1. PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest
in any manner. RHB is not registered as a broker-dealer in the United States and in the securities of the subject company(ies) covered in this report.
currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer For the avoidance of doubt, interest in securities include the following:
brokerage services to U.S. persons. Any order for the purchase or sale of all securities a) Holding directly or indirectly, individually or jointly own/hold securities or
discussed herein must be placed with and through a registered U.S. broker-dealer as entitled for dividends, interest or proceeds from the sale or exercise of the
appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For subject company’s securities covered in this report*;
avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer b) Being bound by an agreement to purchase securities or has the right to transfer
during the issuance of this report. This report is confidential and not intended for the securities or has the right to pre subscribe the securities*.
distribution to, or use by, persons other than the recipient and its employees, agents and c) Being bound or required to buy the remaining securities that are not
advisors, as applicable. Additionally, where research is distributed via Electronic Service subscribed/placed out pursuant to an Initial Public Offering*.
Provider, the analysts whose names appear in this report are not registered or qualified d) Managing or jointly with other parties managing such parties as referred to in
as research analysts in the United States and are not associated persons of any (a), (b) or (c) above.
registered U.S. broker-dealer as appointed by RHB from time to time and therefore may 2. PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market
not be subject to any applicable restrictions under Financial Industry Regulatory products of the subject company(ies) covered in this report.
Authority (“FINRA”) rules on communications with a subject company, public 3. None of PT RHB Sekuritas Indonesia’s staff** or associated person serve as a
appearances and personal trading. Investing in any non-U.S. securities or related director or board member* of the subject company(ies) covered in this report.
financial instruments discussed in this research report may present certain risks. The 4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking
securities of non-U.S. issuers may not be registered with, or be subject to the regulations or corporate finance services from the subject company in the past 12 months.
of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or 5. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including
related financial instruments may be limited. Foreign companies may not be subject to gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in
audit and reporting standards and regulatory requirements comparable to those in the relation to the production of this report:
United States. The financial instruments discussed in this report may not be suitable for
all investors. Transactions in foreign markets may be subject to regulations that differ Notes:
from or offer less protection than those in the United States. *The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.
**The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.
DISCLOSURE OF CONFLICTS OF INTEREST Singapore
RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and Save as disclosed in the following link RHB Research Conflict Disclosures - Nov 2024
associated companies, (“RHBIB Group”) form a diversified financial group, undertaking and to the best of our knowledge, the Singapore Research department of RHB Bank
various investment banking activities which include, amongst others, underwriting, Berhad (through its Singapore branch) hereby declares that:
securities trading, market making and corporate finance advisory. 1. RHB Bank Berhad, its subsidiaries and/or associated companies do not make a
market in any issuer covered by the Singapore research analysts in this report.
As a result of the same, in the ordinary course of its business, any member of the RHBIB
2. RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts
Group, may, from time to time, have business relationships with, hold any positions in
do not have a financial interest (including a shareholding of 1% or more) in the
the securities and/or capital market products (including but not limited to shares,
issuer covered by the Singapore research analysts in this report.
warrants, and/or derivatives), trade or otherwise effect transactions for its own account
3. RHB Bank Berhad’s Singapore research staff or connected persons do not serve
or the account of its customers or perform and/or solicit investment, advisory or other
on the board or trustee positions of the issuer covered by the Singapore research
services from any of the subject company(ies) covered in this research report.
analysts in this report.
While the RHBIB Group will ensure that there are sufficient information barriers and 4. RHB Bank Berhad, its subsidiaries and/or its associated companies do not have
internal controls in place where necessary, to prevent/manage any conflicts of interest and have not within the last 12 months had any corporate finance advisory
to ensure the independence of this report, investors should also be aware that such relationship with the issuer covered by the Singapore research analysts in this
conflict of interest may exist in view of the investment banking activities undertaken by report or any other relationship that may create a potential conflict of interest.
the RHBIB Group as mentioned above and should exercise their own judgement before 5. RHB Bank Berhad’s Singapore research analysts, or person associated or
making any investment decisions. connected to it do not have any interest in the acquisition or disposal of, the
In Singapore, investment research activities are conducted under RHB Bank Berhad securities, specified securities based derivatives contracts or units in a collective
(through its Singapore branch), and the disclaimers above similarly apply. investment scheme covered by the Singapore research analysts in this report.
6. RHB Bank Berhad’s Singapore research analysts do not receive any compensation
Malaysia or benefit in connection with the production of this research report or
Save as disclosed in the following link RHB Research Conflict Disclosures - Nov 2024 recommendation on the issuer covered by the Singapore research analysts.
and to the best of our knowledge, RHBIB hereby declares that:
1. RHBIB does not have a financial interest in the securities or other capital market Analyst Certification
products of the subject company(ies) covered in this report. The analyst(s) who prepared this report, and their associates hereby, certify that:
2. RHBIB is not a market maker in the securities or capital market products of the (1) they do not have any financial interest in the securities or other capital market
subject company(ies) covered in this report. products of the subject companies mentioned in this report, except for:
3. None of RHBIB’s staff or associated person serve as a director or board member* of
the subject company(ies) covered in this report Analyst Company
- -
24
(2) no part of his or her compensation was, is or will be directly or indirectly related to
the specific recommendations or views expressed in this report.
BANGKOK SINGAPORE
RHB Securities (Thailand) PCL RHB Bank Berhad (Singapore branch)
10th Floor, Sathorn Square Office Tower 90 Cecil Street
98, North Sathorn Road, Silom #04-00 RHB Bank Building
Bangrak, Bangkok 10500 Singapore 069531
Thailand Fax: +65 6509 0470
Tel: +66 2088 9999
Fax :+66 2088 9799
25